Delaware
|
000-15751
|
56-1764501
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
Exhibit Number
|
Description
|
|
eMagin Corporation
(Registrant)
|
|||
Date: May 14, 2014
|
By:
|
/s/ Paul Campbell | |
Paul Campbell | |||
Chief Financial Officer | |||
Exhibit Number
|
Description
|
|
99.1
|
Press Release of eMagin Corporation dated May 13, 2014
|
● | eMagin continued deliveries of microdisplay products to more than 85 domestic and international customers. These include display shipments for the FELIN Soldier Modernization Program in France, BAE/Oasys, FLIR in Sweden for three industrial thermal camera EVFs, and BCF Technology in Scotland for the BUG Binocular Ultrasound Goggles, |
● | eMagin’s new OLED deposition tool had its best quarter yet in terms of up-time. | |
● | The Company terminated two license agreements and settled litigation with Global OLED Technology, LLC., in exchange for mutual releases and the payment by eMagin of a one-time, undisclosed settlement amount. | |
● | Samples of the high luminance XLS and XLT technologies were delivered and are being added to the system architecture for both commercial and military applications. As a result of further R&D efforts, the already existing high brightness OLED-XLS product’s lifetime was improved by about 25 percent. The full qualification of these displays as a product is expected to be completed by the third quarter of 2014. | |
● | Progress was made toward building a tool for the ultra-high brightness and high resolution directly patterned color OLED devices. A prototype ultra-high resolution high brightness OLED display is expected to be fabricated in the third quarter of 2014. | |
● | eMagin’s R&D team developed a new seal structure that can increase the overall yield and reliability of the Company’s products. A large portion of the work toward qualifying this seal structure was completed during the first quarter. | |
● | eMagin expects to complete production qualification of its new DSVGA display in the second quarter and release the display for production by the end of 2014. This display is targeted for the next generation of enhanced night vision goggles. | |
● | First samples of the SXGA096 product are expected to be available in the second quarter. The SXGA096 will provide eMagin’s customers with the high resolution of an SXGA display but with a smaller form factor and lower cost of production than larger pixel SXGA displays. | |
● | On May 9, management presented to institutional investors at the Sidoti Semi-Annual Microcap Conference in New York. |
March 31, 2014
(unaudited)
|
December 31, 2013
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
2,063
|
$
|
4,032
|
||||
Investments
|
5,750
|
6,250
|
||||||
Accounts receivable, net
|
4,753
|
4,319
|
||||||
Inventories, net
|
4,740
|
3,434
|
||||||
Prepaid expenses and other current assets
|
773
|
745
|
||||||
Total current assets
|
18,079
|
18,780
|
||||||
Long-term investments
|
500
|
750
|
||||||
Equipment, furniture and leasehold improvements, net
|
9,196
|
9,119
|
||||||
Other assets
|
27
|
27
|
||||||
Total assets
|
$
|
27,802
|
$
|
28,676
|
||||
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
1,830
|
$
|
1,470
|
||||
Accrued expenses
|
2,656
|
2,812
|
||||||
Other current liabilities
|
380
|
395
|
||||||
Total current liabilities
|
4,866
|
4,677
|
||||||
Commitments and contingencies
|
||||||||
Shareholders’ equity:
|
||||||||
Preferred stock, $.001 par value: authorized 10,000,000 shares:
|
||||||||
Series B Convertible Preferred stock, (liquidation preference of $5,659,000) stated value $1,000 per share, $.001 par value: 10,000 shares designated and 5,659 issued and outstanding as of March 31, 2014 and December 31, 2013
|
—
|
—
|
||||||
Common stock, $.001 par value: authorized 200,000,000 shares, issued and outstanding, 23,989,902 shares as of March 31, 2014 and 23,928,619 as of December 31, 2013
|
24
|
24
|
||||||
Additional paid-in capital
|
226,606
|
226,051
|
||||||
Accumulated deficit
|
(203,194
|
)
|
(201,576
|
)
|
||||
Treasury stock, 162,066 shares as of March 31, 2014 and December 31, 2013
|
(500
|
)
|
(500
|
)
|
||||
Total shareholders’ equity
|
22,936
|
23,999
|
||||||
Total liabilities and shareholders’ equity
|
$
|
27,802
|
$
|
28,676
|
Three Months Ended
|
||||||||
March 31,
|
||||||||
2014
|
2013
|
|||||||
Revenue:
|
||||||||
Product
|
$
|
6,259
|
$
|
8,129
|
||||
Contract
|
19
|
374
|
||||||
Total revenue, net
|
6,278
|
8,503
|
||||||
Cost of goods sold:
|
||||||||
Product
|
4,332
|
4,537
|
||||||
Contract
|
15
|
215
|
||||||
Total cost of goods sold
|
4,347
|
4,752
|
||||||
Gross profit
|
1,931
|
3,751
|
||||||
Operating expenses:
|
||||||||
Research and development
|
1,426
|
1,190
|
||||||
Selling, general and administrative
|
2,119
|
2,239
|
||||||
Total operating expenses
|
3,545
|
3,429
|
||||||
(Loss) income from operations
|
(1,614
|
)
|
322
|
|||||
Other income (expense):
|
||||||||
Interest expense, net
|
(11
|
)
|
(11
|
)
|
||||
Other income, net
|
7
|
14
|
||||||
Total other income (expense), net
|
(4
|
)
|
3
|
|||||
(Loss) income before provision for income taxes
|
(1,618
|
)
|
325
|
|||||
Provision for income taxes
|
—
|
120
|
||||||
Net (loss) income
|
$
|
(1,618
|
)
|
$
|
205
|
|||
Less net income allocated to participating securities
|
—
|
50
|
||||||
Net (loss) income allocated to common shares
|
$
|
(1,618
|
)
|
$
|
155
|
|||
(Loss) income per share, basic
|
$
|
(0.07
|
)
|
$
|
0.01
|
|||
(Loss) income per share, diluted
|
$
|
(0.07
|
)
|
$
|
0.01
|
|||
Weighted average number of shares outstanding:
|
||||||||
Basic
|
23,778,110
|
23,527,072
|
||||||
Diluted
|
23,778,110
|
25,332,976
|
Three Months Ended
|
||||||||
March 31,
|
||||||||
2014
|
2013
|
|||||||
Net (loss) income
|
$ | (1,618 | ) | $ | 205 | |||
Litigation expense
|
116 | — | ||||||
Adjusted net (loss) income
|
(1,502 | ) | 205 | |||||
Non-cash compensation
|
490 | 619 | ||||||
Depreciation and amortization expense
|
256 | 204 | ||||||
Interest expense
|
11 | 11 | ||||||
Income tax expense (benefit)
|
— | 120 | ||||||
Adjusted EBITDA
|
$ | (745 | ) | $ | 1,159 |